Navigation Links
BrainCells Inc. Appoints David E. Thompson to Its Board of Directors

SAN DIEGO, Dec. 2 /PRNewswire/ -- BrainCells Inc. (BCI), a biopharmaceutical company utilizing its platform technology to identify and develop compounds that promote the growth of new neurons for the treatment of central nervous system (CNS) diseases, announced today the appointment of David E. Thompson to its board of directors. Thompson is a veteran of the pharmaceutical industry, with a 30-year tenure at Eli Lilly and Co. where he focused on building the company while leading corporate strategy, business development, corporate ventures and alliance management.

"Dave is an industry veteran with broad experience and numerous relationships in the pharmaceutical and biotech world," said Jim Schoeneck, BrainCells CEO. "He will be a valuable resource as we execute corporate strategy and potential transactions around our neurogenesis platform technology and compounds in clinical development, including BCI-540, for which we anticipate Phase II data for the treatment of depression and anxiety in 2009."

Thompson conducted a successful 30-year career at Eli Lilly and its affiliates which culminated in a position as vice president of corporate strategy and business development. During his tenure at Eli Lilly, Thompson focused his expertise on all aspects of Lilly's business, holding numerous positions including director of corporate new product planning and licensing, president and general manager of Eli Lilly Canada, president/CEO of IVAC Corporation and vice president of pharmaceutical product management and licensing. Currently, Thompson is executive chairman of Bayhill Therapeutics, Inc. and is a member of the board of directors for Anthera Pharmaceuticals, Inc. Born in Lansing, Michigan, he is a graduate of Michigan State University with a BS and MBA.

"BCI's scientific application of neurogenesis for the treatment of mood disorders and other CNS diseases has the potential to revolutionize the way drugs are developed to treat neurological conditions," said Thompson. "I look forward to working with the BCI management team and its board as they continue to move product candidates forward."

"Dave is an exceptional addition to our board of directors," commented Dr. Harry Hixson, BrainCells' chairman of the board. "His in-depth experience in business development, licensing and operations will be a great asset to us as we continue to expand our neurogenic platform technology and to explore potential strategic collaborations."

About BCI-540

BCI-540 is in Phase IIa clinical studies for the treatment of depression with anxiety in patients who have not responded to current therapies. It has a mechanism of action distinct from any marketed anti-depressant by acting as a neurogenic agent directly on in vitro human neural stem cells, unlike an SSRI which acts by an indirect mechanism, which may eliminate serotonin associated side effects. BCI-540 was in-licensed from Mitsubishi Pharma (MPC) based on its neurogenic properties and in previous studies was shown to be well tolerated in more than 900 subjects in Phase I and II clinical trials.

About BrainCells Inc.

BrainCells Inc. (BCI) is a San Diego-based drug discovery and development company that is applying its proprietary neurogenesis platform technology to identify and reposition compounds for the treatment of central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and development of neurogenic compounds, increasing the opportunity for successful clinical trials in a variety of CNS indications. For more information, visit

     Media Contact:

     BrainCells Inc.
     Kim Richards
     Porter Novelli Life Sciences

SOURCE BrainCells Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. REVISED: BrainCells Inc. Expands Series B Financing to $50 Million
2. BrainCells Inc. Expands Series B Financing to $50 Million
3. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
4. Cerimon Pharmaceuticals Appoints James S. Shannon, M.D., to Board of Directors
5. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
6. InCode BioPharmaceutics Appoints New President and CEO
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. GeneNews appoints Canadian Colorectal Cancer Advisory Board
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
11. Accumetrics Appoints John J. Young, MD Chief Medical Officer
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
Breaking Biology News(10 mins):